This story originally ran on Sept. 14.
Swedish protein detection and analysis firm Olink Bioscience and its sister company, Olink Genomics, today announced their participation in a project to improve the survival rate of patients with colorectal cancer.
The project, called "Companion Diagnostics Initiative" is financed by the Swedish Governmental Agency for Innovation Systems. The amount of funding was not disclosed. Mats Nilsson, a professor in genetics and pathology at Uppsala University is coordinating the project.
Olink Bioscience will contribute to the effort its in situ PLA proximity ligation assay technology for the detection of proteins, protein interactions, and modifications. Olink Genomics will provide its Selector Technology to overcome bottlenecks associated with targeted resequencing using next-generation sequencing instruments.
In a statement Björn Ekström, CEO of Olink Bioscience said that combining the PLA technology with the Selector Technology will enable "monitoring both the activation status of signaling pathways on the protein level and the mutation status on the genetic level. Together, these tools provide access to a unique picture of the molecular basis of cancer and the response to targeted cancer treatment."